会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Spiro�heterocycle-imidazo�1,2-a!indeno�1,2-e!pyrazine!-4'-ones,
preparation thereof and drugs containing same
    • 螺[杂环咪唑并[1,2-a]茚并[1,2-e]吡嗪] -4'-酮,其制备方法和含有它们的药物
    • US5777114A
    • 1998-07-07
    • US836410
    • 1997-06-30
    • Jean-Claude AloupFran.cedilla.ois AudiauMichel BarreauDominique DamourArielle Genevois-BorellaPatrick JimonetSerge MignaniYves Ribeill
    • Jean-Claude AloupFran.cedilla.ois AudiauMichel BarreauDominique DamourArielle Genevois-BorellaPatrick JimonetSerge MignaniYves Ribeill
    • C07D487/04A61K31/495A61P9/02A61P9/08A61P9/10A61P9/14A61P11/00A61P25/00A61P25/28A61P43/00C07D471/20C07D487/20C07D471/235C07D487/241
    • C07D471/20C07D487/20
    • Compounds of formula (I): ##STR1## wherein R.sub.3 and R.sub.4, taken together with the carbon atom to which they are attached, form (a) a 2- or 3-pyrrolidine ring, a 2- or 4-piperidine ring or a 2-azacycloheptane ring, said rings being optionally substituted at the nitrogen atom by an alkyl, --CHO, --COOR.sub.11, --CO--alk--COOR.sub.6, --CO--alk--NR.sub.6 R.sub.12, --CO--alk--CONR.sub.6 R.sub.8, --CO--COOR.sub.6, --CO--CH.sub.2 --O--CH.sub.2 --COOR.sub.6, --CO--CH.sub.2 --S--CH.sub.2 --COOR.sub.6, --CO--CH.dbd.CH--COOR.sub.6, CO--alk, --CO--Ar", --CO--alk--Ar", --CO--NH--Ar", --CO--NH--alk--Ar", --CO--Het, --CO--alk--Het, --CO--NH--Het, --CO--NH--alk--Het, --CO--NH.sub.2, --CO--NH--alk, --CO--N(alk)alk', --CS--NH.sub.2, --CS--NH--alk, --CS--NH--Ar", --CS--NH--Het, --alk--Het, --alk--NR.sub.6 R.sub.8, --alk--COOR.sub.6, --alk--CO--NR.sub.6 R.sub.8, --alk--Ar", --SO.sub.2 --alk or --SO.sub.2 --Ar radical, or a --CO-cycloalkyl radical where the cycloalkyl is optionally 2-substituted by a carboxyl radical; or (b) a 2-pyrrolidin-5-one ring. The compounds of formula (I) have useful pharmacological properties and are .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, said receptor also being known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, and especially NMDA receptor glycine modulation site ligands.
    • PCT No.PCT / FR95 / 01430 Sec。 371日期:1997年6月30日 102(e)日期1997年6月30日PCT 1995年10月30日PCT PCT。 WO96 / 14318 PCT公开号 日期:1996年5月17日式(I)化合物:其中R 3和R 4与它们所连接的碳原子一起形成(a)2-或3-吡咯烷环, 或4-哌啶环或2-氮杂环庚烷环,所述环任选在氮原子上被烷基,-CHO,-COOR11,-CO-烷基-COOR6,-CO-alk-NR6R12,-CO- CONR6R8,-CO-COOR6,-CO-CH2-O-CH2-COOR6,-CO-CH2-S-CH2-COOR6,-CO-CH = CH-COOR6,-CO-烷基,-CO-Ar“ CO-NH-Ar“,-CO-NH-alk-Ar”,-CO-Het,-CO-alk-Het,-CO-NH-Het,-CO- NH-alk-Het,-CO-NH2,-CO-NH-alk,-CO-N(alk)alk',-CS-NH2,-CS-NH-alk,-CS-NH-Ar“ CS-NH-Het,-alk-Het,-alk-NR6R8,-alk-COOR6,-alk-CO-NR6R8,-alk-Ar“,-SO2-alk或-SO2-Ar基,或-CO - 环烷基,其中环烷基任选被羧基任意地2-取代; 或(b)2-吡咯烷-5-酮环。 式(I)化合物具有有用的药理学性质,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体拮抗剂,所述受体也称为quisqualate受体。 此外,式(I)化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,特别是NMDA受体甘氨酸调节位点配体。
    • 10. 发明授权
    • Complexes derived from platinum, their preparation and the
pharmaceutical compositions which contain them
    • 衍生自铂的复合物,其制备物和含有它们的药物组合物
    • US5225207A
    • 1993-07-06
    • US775410
    • 1991-10-15
    • Michel BarreauJean-Claude ChottardJean-Bernard Le PecoPatrick Mailliet
    • Michel BarreauJean-Claude ChottardJean-Bernard Le PecoPatrick Mailliet
    • C07F15/00
    • C07F15/0093
    • New complexes of general formula (I) in whichR.sub.1 and R.sub.2 together form a saturated or unsaturated polycyclic carbocyclic radical containing 7 to 12 carbon atoms, or a saturated or partially saturated mono-, bi- or tricyclic heterocyclic radical containing 5 to 11 chain members and a hetero-atom chosen from oxygen, sulphur or nitrogen, which latter atom can optionally be substituted by an alkoxycarbonyl radical, and,X.sub.1 and X.sub.2 represent chlorine atoms or together formeither a radical of structure: ##STR1## in which n is 0 to 2 and R.sub.6 and R.sub.7, which are identical or different, are hydrogen atoms or, when n=1, can be alkyl radicals or form, together with the carbon atom to which they are attached, a cyclobutyl radical,or a radical of structure: ##STR2## in which n, R.sub.6 and R.sub.7 are defined as above, or their salts where such exist, and their hydrates, their preparation and the pharmaceutical compositions which contain them. ##STR3##
    • 通式(I)的新络合物,其中R 1和R 2一起形成含有7至12个碳原子的饱和或不饱和多环碳环基团,或含有5至11个链成员的饱和或部分饱和的单,双或三环杂环基团 和选自氧,硫或氮的杂原子,其后一个原子可任选被烷氧基羰基取代,并且,X 1和X 2表示氯原子或一起形成结构式如下的基团:其中 n为0〜2,R6和R7为相同或不同的氢原子,n = 1时,可以为烷基,也可以与它们所连接的碳原子一起形成环丁基或 结构基团:其中n,R6和R7如上所定义,或其盐,如此存在,以及它们的水合物,它们的制备和含有它们的药物组合物。 (一)